{"id":"W2597889315","doi":"10.1200/jco.2009.27.15_suppl.4609","title":"Phase II trial of erlotinib in advanced pancreatic cancer (PC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Erlotinib; Medicine; Rash; Gemcitabine; Internal medicine; Adverse effect; Gastroenterology; Epidermal growth factor receptor; Erlotinib Hydrochloride; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001492953,0.001674147,0.001989273,0.0003146989,0.0003907981,0.0009343873,0.0007080741,0.001282035,0.007244709],"category_scores_gemma":[0.0007678387,0.000514102,0.0007887979,0.0003846654,0.0006529883,0.0007637835,0.000481359,0.002928,0.001695584],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007258159,"about_ca_system_score_gemma":0.001344335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006492275,"about_ca_topic_score_gemma":0.001452964,"domain_scores_codex":[0.9996605,0.0001639207,0.00002123708,0.00005736226,0.00002693584,0.00007011134],"domain_scores_gemma":[0.9994625,0.0001000653,0.00009969367,0.00005035802,0.00003519951,0.0002522187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8082162,0.05315443,0.004631009,0.001356054,0.00089898,0.000404433,0.000232505,0.00327278,0.0255577,0.0003552686,0.008391335,0.0935293],"study_design_scores_gemma":[0.7647178,0.2222519,0.005163649,0.0000429463,0.0002154552,0.0003577536,0.00003434849,0.00138278,0.00221202,0.000188201,0.003413445,0.00001974647],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825249,0.002691096,0.001047948,0.001004324,0.0002916229,0.005952666,0.002130774,0.0002094618,0.004147201],"genre_scores_gemma":[0.9745905,0.00254184,0.002425251,0.00155582,0.0002707464,0.006070927,0.004754612,0.00005189232,0.007738553],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007244709,"threshold_uncertainty_score":0.02423596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2025583055939127,"score_gpt":0.5849707875033292,"score_spread":0.3824124819094165,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}